Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 10/20 | 0.39 |
| ▸ | INSR | P06213 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24620485 | 0.87 | BTK (0.47) | MAP4K1ALKBTKAXLTYRO3 | |
| SCHEMBL24620351 | 0.85 | MAP4K1 (0.51) | MAP4K1ALKBTKEGFR | |
| SCHEMBL24620455 | 0.77 | MAP4K1 (0.51) | MAP4K1ALKBTKAXLTYRO3 | |
| SCHEMBL24620240 | 0.77 | MAP4K1 (0.54) | MAP4K1 | |
| SCHEMBL24620199 | 0.76 | IGF1R (0.34) | IGF1RPKMYT1 | |
| SCHEMBL24620227 | 0.76 | MAP4K1 (0.54) | MAP4K1ALKINSR | |
| SCHEMBL24620276 | 0.76 | BTK (0.45) | MAP4K1ALKBTK | |
| SCHEMBL24620447 | 0.76 | BTK (0.40) | MAP4K1ALKINSRBTKEGFR | |
| SCHEMBL24620488 | 0.75 | MAP4K1 (0.42) | MAP4K1ALKBTK | |
| SCHEMBL24620230 | 0.72 | MAP4K1 (0.54) | MAP4K1ALKMETAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022147622-A1 | ISOINDOLINONE AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-07-14 | — | — | WO | disclosed |